W. Lofters - Concepedia

Author

W. Lofters

National Cancer Institute

Also Known As

Lofters, W., W Lofters, W S Lofters, W. Lofters, W. S. Lofters, W.S. Lofters, Wycliff Lofters, Wycliff S. Lofters

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute University of the West Indies Queen's University McMaster University Ontario Institute for Cancer Research

About

W. Lofters is an author at National Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	511
2	Pathology	5	5	232
3	Pharmacology	5	5	339
4	Immunology	3	3	109
5	Health Sciences	1	1	37

W. Lofters

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Modelling the risk of adult T‐cell leukemia/lymphoma in persons infected with human T‐lymphotropic virus type I Edward L. Murphy, B Hanchard, J. Peter Figueroa, International Journal of Cancer	1989	402
Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. M E Trudeau, Elizabeth A. Eisenhauer, B P Higgins, Journal of Clinical Oncology	1996	161
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8 B. Norris, Kathleen I. Pritchard, K. James, Journal of Clinical Oncology National Cancer InstituteMetastatic Breast CancerOncologyBreast OncologyMedicine	2000	143
Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. L Kaizer, David Warr, Paul Hoskins, Journal of Clinical Oncology	1994	116
Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. W. Lofters, Joseph L. Pater, Benny Zee, Journal of Clinical Oncology	1997	102
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study C. Cripps, Margot J. Burnell, Jacques Jolivet, Annals of Oncology OncologyMulti-targeted AntifolateMedicinePathologyColorectal Cancer	1999	97
Seroepidemiologic Studies Of Human T‐cell leukemia/lymphoma virus type I in Jamaica Jeffrey W. Clark, Arthur Ensroth, William A. Blattner, International Journal of Cancer	1985	73
The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy Joseph L. Pater, W. Lofters, Benny Zee, Annals of Oncology Emetogenic ChemotherapyOncologyMedicineMetronomic TherapyDelayed Onset Nausea	1997	68
Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis David Warr, Andrew R. Willan, Shai Fine, JNCI Journal of the National Cancer Institute	1991	56
Cytogenetic Studies in Human T-cell Lymphoma Virus (HTLV)-Positive Leukemia-Lymphoma in the United States J. Whang‐Peng, Bunn Pa, Turid Knutsen, JNCI Journal of the National Cancer Institute Mixed-phenotype Acute LeukemiaImmunologyPathologyUnited StatesCancer-associated Virus	1985	46

Page 1